A phase I study of interleukin-2 in children with cancer
M Roper, MA Smith, PM Sondel… - Journal of pediatric …, 1992 - journals.lww.com
Abstract Recombinant interleukin-2 (IL-2) produces clinical responses in–20% of adult
patients with renal cell carcinoma and melanoma, with both high-dose bolus and continuous
infusion regimens. Because of the lower toxicity of continuous infusion, we elected to
investigate in a Phase I trial a 5-day continuous infusion repeated for three weeks in children
with malignancies refractory to standard therapy. Nineteen children with solid tumors and
eight children with hematologic malignancies were entered into the study. The maximum …
patients with renal cell carcinoma and melanoma, with both high-dose bolus and continuous
infusion regimens. Because of the lower toxicity of continuous infusion, we elected to
investigate in a Phase I trial a 5-day continuous infusion repeated for three weeks in children
with malignancies refractory to standard therapy. Nineteen children with solid tumors and
eight children with hematologic malignancies were entered into the study. The maximum …